Although new-onset DM had not been reported in clinical trials involving CTLA-4 inhibitors, it had been reported in <1% of patients included clinical trials on PD-1 inhibitors, with higher rates (up to 1.5%) being observed with the combined use of CTLA-4 and PD-1 inhibitors (87). The gene discussed is CTLA4; the disease is diabetes mellitus.